SEC Company Response from Scopus BioPharma Inc. (SCPS) (CIK 0001772028) — Jan 26, 2021
Scopus BioPharma Inc. (SCPS) (CIK 0001772028)
Date: Jan. 26, 2021 · CIK: 0001772028 · Accession: 0001104659-21-007536
AI Filing Summary & Sentiment
File numbers found in text: 024-11228
Letter
Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission File No.: 024-11228 Acceleration Request Requested Date: January 26, 2021 Requested Time: 5:00 P.M. Eastern Time
Dear Ms. Schwartz:
Scopus BioPharma Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Post Qualification Amendment No. 3 to Form 1-A qualified at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Company hereby authorizes Mark J. Wishner, who is an attorney with the Company’s outside legal counsel, Greenberg Traurig, LLP, to orally modify or withdraw this request for acceleration.
The Company hereby acknowledges that:
· should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing qualified, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing qualified, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
Securities and Exchange Commission
January 26, 2021
Page 2
· the Company may not assert the staff comments and the declaration of qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company also agrees that it will only sell shares of its common stock pursuant to the subject Offering Statement in states where the offering is registered or where there is an applicable exemption from the applicable state’s securities law available.
The Company requests that it be notified of such qualification by a telephone call to Mark J. Wishner at (703) 749-1352 or email to him at: WishnerM@gtlaw.com.
Sincerely,
Scopus BioPharma Inc.
Show Raw Text
CORRESP
1
filename1.htm
Scopus
BioPharma Inc.
420 Lexington Avenue, Suite 300
New York, NY 10170
January 26, 2021
Ms. Margaret Schwartz
Division of Corporation Finance
Office of Life Sciences
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re:
Scopus BioPharma Inc.
Post Qualification Amendment No. 3 to Form 1-A
Filed: January 26, 2021
File No.: 024-11228
Acceleration Request
Requested Date: January
26, 2021
Requested Time: 5:00
P.M. Eastern Time
Dear Ms. Schwartz:
Scopus BioPharma Inc. (the “Company”)
hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the
above-captioned Post Qualification Amendment No. 3 to Form 1-A qualified at the “Requested Date” and “Requested
Time” set forth above or as soon thereafter as practicable.
The Company hereby authorizes Mark J. Wishner,
who is an attorney with the Company’s outside legal counsel, Greenberg Traurig, LLP, to orally modify or withdraw this request
for acceleration.
The Company hereby acknowledges that:
· should
the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing qualified, it does not
foreclose the Commission from taking any action with respect to the filing;
· the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing qualified, does not relieve
the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
Securities and Exchange Commission
January 26, 2021
Page 2
· the
Company may not assert the staff comments and the declaration of qualification as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.
The Company also agrees that it will only
sell shares of its common stock pursuant to the subject Offering Statement in states where the offering is registered or where
there is an applicable exemption from the applicable state’s securities law available.
The Company requests that it be notified
of such qualification by a telephone call to Mark J. Wishner at (703) 749-1352 or email to him at: WishnerM@gtlaw.com.
Sincerely,
Scopus BioPharma Inc.
By:
/s / Joshua R. Lamstein
Name:
Joshua R. Lamstein
Title:
Chairman